List view / Grid view
21 May 2015 | By Victoria White
Alnylam has filed a Clinical Trial Application to initiate a Phase 1/2 clinical trial with ALN-AAT for the treatment of alpha-1 liver disease...
We discuss the steps required for differentiating human pluripotent stem cells into hepatocyte-like cells, and how long this process takes and the quality control measures needed...
13 November 2014 | By Bristol-Myers Squibb
The Partnering for Cure faculty of experts announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the potential development of cure strategies in HIV, hepatitis B (HBV) and hepatitis C (HCV)...
6 May 2014 | By Red Door Communications
New evidence published to coincide with the International Liver Meeting showing the potential for elimination of hepatitis C across 15 countries by 2030...
10 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir...
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...
